{"id":"NCT04652102","sponsor":"CureVac","briefTitle":"A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older","officialTitle":"COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-12-11","primaryCompletion":"2022-06-10","completion":"2022-06-10","firstPosted":"2020-12-03","resultsPosted":"2024-04-29","lastUpdate":"2024-04-29"},"enrollment":39680,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Covid19","SARS-CoV-2"],"interventions":[{"type":"BIOLOGICAL","name":"CVnCoV","otherNames":["CV07050101"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program","otherNames":[]}],"arms":[{"label":"Randomized Observer-blinded Phase 2b: CVnCoV vaccine","type":"EXPERIMENTAL"},{"label":"Randomized Observer-blinded Phase 2b: Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Randomized Observer-blinded Phase 3: CVnCoV vaccine","type":"EXPERIMENTAL"},{"label":"Randomized Observer-blinded Phase 3: Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Open-label Phase","type":"EXPERIMENTAL"}],"summary":"The primary objective of the randomized observer-blinded phase 2b/3 part of this trial is to demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed cases of COVID-19 of any severity in SARS-CoV-2 naïve participants.","primaryOutcome":{"measure":"Number of Participants Who Experienced a First Episode of Virologically-confirmed {Reverse Transcription Polymerase Chain Reaction (RT-PCR) Positive} Case of COVID-19 of Any Severity","timeFrame":"Day 44 to Day 393","effectByArm":[{"arm":"CVnCoV 12 μg Vaccine","deltaMin":83,"sd":null},{"arm":"Placebo","deltaMin":145,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"0.01600"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":16},"locations":{"siteCount":46,"countries":["Argentina","Belgium","Colombia","Dominican Republic","Germany","Mexico","Netherlands","Panama","Peru","Spain"]},"refs":{"pmids":["34826381"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":149,"n":19787},"commonTop":["Headache","Fatigue","Injection site pain","Myalgia","Chills"]}}